IRCT201610098983N2
Completed
Phase 2
Evaluation of therapeutic effect intravitreal injection of methotrexate in persistent diabetic macular edema
Guilan University of Medical Sciences,Vice chancellor for research0 sites42 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Resistant macular edema in diabetic patients.
- Sponsor
- Guilan University of Medical Sciences,Vice chancellor for research
- Enrollment
- 42
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient with central subfleid thickness (CST) More than 250 micrometers.
- •2\. Best corrected visual acuity 20/ 200 and more.
- •3\.lack of one line improvement, at least, in best corrected visual acuity or at least 10% reduction in central subfield thickness after intravitreal injection of three consecutive Bevacizumab and one injection co\-administration bevacizumab \-triamcinolone every 4\-6week intervalor 3 consecutive Bevacizumab every 4 \-6 weeks plus macular photouagulation.
- •4\. Lack of traction on the macula, which is identified on clinical examination and OCT
- •5\. Patient who agree entering the study (consent form)
- •Exclusion criteria :
- •1\. Any previous intraocular surgery that was done in more than 1year ago
- •2\. Any laser photocuagulation treatment in the past 4 months .
- •3\. Need to any intraocular surgery, intraocular injection or laser photocoagulation in the follow\-up period .
- •4\. Any traction on the macula which is identified on clinical examination and OCT.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The Comparison of Efficacy Between Iranian Made Ranibizumab and Imported Ranibizumab in Diabetic Patients with Macular EdemaIRCT20170303032845N1Aracell zist daru154
Completed
Phase 3
The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edemadiabetic macular edemaJPRN-UMIN000017037Jichi Medica University, Saitama Medical Center100
Active, not recruiting
Not Applicable
Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma - NDMacular oedemaMedDRA version: 6.1Level: HLGTClassification code 10047060EUCTR2006-002351-33-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSAEUCTR2006-003170-99-ITIVERSITA DEGLI STUDI DI UDINE
Recruiting
Phase 1
Comparison of the effect of intravitreal injection of bevacizumab (Stevenet) alone with intravitreal injection of bevacizumab and triamcinolone in the treatment of diabetic macular edema with a thickness greater than 500 microns in patientsIRCT20211130053229N1Kerman University of Medical Sciences70